Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance

被引：38
|
作者：
Nolan, D
Phillips, E
Mallal, S
机构：
[1] Murdoch Univ, Ctr Clin Immunol & Biomed Stat, Royal Perth Hosp, Perth, WA 6000, Australia
[2] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 03期
关键词：
D O I：
10.1086/499369
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：408 / 410
页数：3
相关论文
共 50 条
  • [21] Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
    Hesse, LM
    von Moltke, LL
    Shader, RI
    Greenblatt, DJ
    DRUG METABOLISM AND DISPOSITION, 2001, 29 (02) : 100 - 102
  • [22] Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism
    Sukasem, C.
    Manosuthi, W.
    Koomdee, N.
    Santon, S.
    Jantararoungtong, T.
    Prommas, S.
    Chamnanphol, M.
    Puangpetch, A.
    Sungkanuparph, S.
    INFECTION, 2014, 42 (03) : 469 - 474
  • [23] Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism
    C. Sukasem
    W. Manosuthi
    N. Koomdee
    S. Santon
    T. Jantararoungtong
    S. Prommas
    M. Chamnanphol
    A. Puangpetch
    S. Sungkanuparph
    Infection, 2014, 42 : 469 - 474
  • [24] CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
    Metzger, Ingrid F.
    Dave, Nimita
    Kreutz, Yvonne
    Lu, Jessica B. L.
    Galinsky, Raymond E.
    Desta, Zeruesenay
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, : 657 - 666
  • [25] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [26] Efavirenz-associated CNS disorders linked to CYP2B6 variant
    Reactions Weekly, 2005, 1035 (1) : 5 - 5
  • [27] Identification of novel cyp2b6 haplotypes in individuals with impaired metabolism of efavirenz
    Wang, J
    Sönnerborg, A
    Rane, A
    Lundgren, S
    Stahle, L
    Ingelman-Sundberg, M
    DRUG METABOLISM REVIEWS, 2005, 37 : 75 - 75
  • [28] CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
    Griesel, Rulan
    Maartens, Gary
    Chirehwa, Maxwell
    Sokhela, Simiso
    Akpomiemie, Godspower
    Moorhouse, Michelle
    Venter, Francois
    Sinxadi, Phumla
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E3902 - E3909
  • [29] Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz
    Wang, Jue
    Sonnerborg, Anders
    Rane, Anders
    Josephson, Filip
    Lundgren, Stefan
    Stahle, Lars
    Ingelman-Sundberg, Magnus
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (03): : 191 - 198
  • [30] The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
    Ward, BA
    Gorski, JC
    Jones, DR
    Hall, SD
    Flockhart, DA
    Desta, Z
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01): : 287 - 300
12345